What is the Rein Therapeutics Inc. stock price forecast?

Rein Therapeutics Inc. is currently trading at $1.22. View real-time AI analysis on Alpha Lenz.

What is Rein Therapeutics Inc. insider trading activity?

View the latest insider trading data for Rein Therapeutics Inc. on Alpha Lenz.

What is Rein Therapeutics Inc.'s P/E ratio?

Rein Therapeutics Inc.'s P/E ratio is -0.3.

Rein Therapeutics Inc.

NASDAQ · RNTX

$1.22+0.05(+4.27%)Market closed

Ask about Rein Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Rein Therapeutics Inc. trades at a P/E of -0.3 (undervalued) with modest ROE of -771.4%.”

Ask for details →

Company Overview

Rein Therapeutics Inc. is a biotechnology company dedicated to developing novel therapies for life-threatening diseases. The primary focus of the company lies in exploring advanced gene editing technologies to create treatments that address unmet clinical needs. Rein Therapeutics Inc. is heavily involved in research and development efforts, often collaborating with leading institutions and pharmaceutical firms to drive innovation in the biotech sector. Its groundbreaking work impacts various fields, particularly in genetic disorders, oncology, and infectious diseases. With headquarters based in a prominent biotech hub, Rein Therapeutics Inc. plays a significant role in the advancement of personalized medicine, delivering potentially transformative therapies to the market. As a publicly traded company, it attracts attention from a diverse range of investors and stakeholders interested in cutting-edge healthcare solutions.

CEODr. James Brian Windsor Ph.D.

Websitehttps://www.reintx.com

SectorHealthcare

IndustryBiotechnology

Employees11

Company Statistics

FY 2024

Profile

$21.89MMarket Cap

$0.00Revenue

0.00Shares Out

11Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-0.35P/E

2.33P/B

N/AEV/Sales

1.04EV/EBITDA

-0.98P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-74.64%ROA

-771.39%ROE

-33.43%ROIC

Financial Health

$12.87MCash & Cash Equivalents

$39.94MNet Debt

562.51%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Rein Therapeutics Inc. trades at a P/E of -0.3 (undervalued) with modest ROE of -771.4%.”

Ask for details →

Frequently Asked Questions

Rein Therapeutics Inc. (ticker: RNTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 11 employees. Market cap is $22M.

The current price is $1.22 with a P/E ratio of -0.35x and P/B of 2.33x.

ROE is -771.39%.